Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants.

NCT00325156 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00325156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00325156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants.
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
November 2, 2004
Completion date
August 23, 2007
Enrollment
2,590 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, diphtheria-tetanus-apertussis-poliomyelitis vaccines, haemophilus influenzae type b, poliomyelitis, tetanus